A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

• David R. Strayer ,

  * E-mail: david.strayer@hemispherx.net (DRS); bill.mitchell@vanderbilt.edu (WMM)

  Affiliation Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania, United States of America

  ⨯
• William A. Carter,

  Affiliation Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania, United States of America

  ⨯
• Bruce C. Stouch,

  Affiliation BCS Consulting, Philadelphia, Pennsylvania, United States of America

  ⨯
• Staci R. Stevens,

  Affiliation University of the Pacific, Stockton, California, United States of America

  ⨯
• Lucinda Bateman,

  Affiliation Fatigue Consultation Clinic, Salt Lake City, Utah, United States of America

  ⨯
• Paul J. Cimoch,

  Affiliation Center for Special Immunology, Fountain Valley, California, United States of America

  ⨯
• Charles W. Lapp,

  Affiliation Hunter-Hopkins Center, Charlotte, North Carolina, United States of America

  ⨯
• Daniel L. Peterson,

  Affiliation Sierra Internal Medicine Associates, Incline Village, Nevada, United States of America

  ⨯
• the Chronic Fatigue Syndrome AMP-516 Study Group ,

  ¶For a list of the members of Chronic Fatigue Syndrome AMP-516 Clinical Study Group please see Table S2.

  ⨯
• William M. Mitchell

  * E-mail: david.strayer@hemispherx.net (DRS); bill.mitchell@vanderbilt.edu (WMM)

  Affiliation Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

  ⨯